Overview

This trial has been completed.

Condition adipose tissue
Treatments venus legacy, coolsculpt
Sponsor Venus Concept
Start date August 2015
End date June 2016
Trial size 10 participants
Trial identifier NCT02569112, CS0915

Summary

The purpose of this study is to evaluate the effect on the subject outcome using the combination of the Zeltiq Cryolipolysis device and the Venus Concept multipolar radiofrequency device with varipulse technology for the enhanced non-surgical treatment of skin laxity in the flank area.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (investigator, outcomes assessor)
Primary purpose treatment
Arm
(Active Comparator)
Each patient is their own control and one side will have only a cryolypolysis (Coolsculpt) treatment while the other side will have both a cryolypolysis treatment and an RF, PEMF and Varipulse (Venus Legacy) treatment
coolsculpt Zeltiq
Cryolipolysis has been developed and commercialized to non-invasively reduce subcutaneous fat. The cryolipolysis technology utilizes the sensitivity of fat cells to cold injury in order to selectively eliminate subcutaneous fat tissue without affecting the skin or other surrounding tissues. Cryolipolysis technology enables a non-invasive alternative for subcutaneous fat reduction through cellular apoptosis.
(Active Comparator)
Each patient is their own control and one side will have only a cryolypolysis (Coolsculpt) treatment while the other side will have both a cryolypolysis treatment and an RF, PEMF and Varipulse (Venus Legacy) treatment
venus legacy
Venus Legacy is a multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse). RF technology works by exciting fat molecules 2-3 million times per second to achieve desired heating effects on fat. RF has been shown to increase the production new collagen and other cell enhancing biological molecules. PEMF delivered in synergy with RF assists in the creation of FGF-2 (fibroblast growth factors 2), TNF-α (tumour necrosis factor-a) and TGF-β (transforming growth factor-b) increasing fibroblasts. Varipulse technology increases the movement of fluids in the lymphatic system and manually stimulates fibroblasts.
coolsculpt Zeltiq
Cryolipolysis has been developed and commercialized to non-invasively reduce subcutaneous fat. The cryolipolysis technology utilizes the sensitivity of fat cells to cold injury in order to selectively eliminate subcutaneous fat tissue without affecting the skin or other surrounding tissues. Cryolipolysis technology enables a non-invasive alternative for subcutaneous fat reduction through cellular apoptosis.

Primary Outcomes

Measure
Visual Improvement
time frame: 6 months

Eligibility Criteria

Male or female participants from 21 years up to 50 years old.

Inclusion Criteria: - Subjects who can read, understand, and sign the Informed Consent Form. - Subjects willing and able to comply with all study requirements. - Subjects who have pre-scheduled a body contouring procedure. - Subjects have clearly visible fat on the flanks, which in the investigator's opinion, may benefit from the treatment. - Subjects have not had weight change exceeding 10 pounds in the preceding month. - Subjects agree to maintain his/her weight (i.e., within 5 pounds) by not making any major changes in their diet or lifestyle during the course of the study. Exclusion Criteria: - Subjects with active localized or systemic infections. - Immuno-compromised subjects. - Pregnant and/or lactating (All female volunteers will be advised about using birth control during the period of study). - In the opinion of the trained clinician, subject is unwilling or unable to adhere to all study requirements, including application and follow-up visits. - Subjects with a history of radiation therapy to the treatment area. - Subjects with any skin pathology or condition that could interfere with evaluation or with the use of typical ancillary medical treatments or care used before, during or after treatments. - Subject has had a surgical procedure(s) in the area of intended treatment. - Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment. - Subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 12 months. - Subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month. - Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria. - Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin. - Subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising. - Subject is taking or has taken diet pills or supplements within the past month. - Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion). - Subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system - Subject has a history of hernia in the areas to be treated. - Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.

Additional Information

Official title Prospective Internally Controlled Blind Reviewed Clinical Evaluation of Cryolipolysis Combined With MP2 Technology for Enhanced Subject Results in Circumferential Fat Reduction and Skin Laxity of the Flanks
Principal investigator Julius Few, MD
Description Commercially available as the Zeltiq CoolSculpting system, cryolipolysis is FDA cleared for use in the United States for an indication of fat layer reduction in the flanks, thighs, and abdomen through cold-assisted lipolysis. CoolSculpting has been clinically proven to non-surgically reduce subcutaneous fat bulges, allowing patients to achieve noticeable and measurable aesthetic results without the pain, expense, downtime, and risks associated with existing invasive and minimally-invasive procedures. The Zeltiq CoolSculpting System is a non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures. The RF device to be used in this study is a FDA cleared device used for aesthetic non-surgical skin tightening procedures including wrinkles, skin rhytides and cellulite in the face and body. The Venus Legacy utilizes a multi-polar radiofrequency system to deliver homogenous heating to multiple tissue depths. The Venus Legacy device also utilizes pulsed magnetic field technology as well as pulsed negative pressure technology. The flanks of Ten (10) healthy adults (male and female), 21 to 50 years of age, who desire a reduction in focal fat of the flanks will be recruited from the investigator's subject populations. Informed Consent will be obtained from each subject during a screening visit. The photos will be taken prior to the treatment series, one week post treatment series, at 3 and 6 months post treatment series for the evaluation of two blinded reviewers as well as for the investigator to assess.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Venus Concept.